Cosmos Health partners with Libytec to commercialize DIABIT-IS X in Greece

Corporate Action
โดย GlobeNewswire·Read original
Summary · why it matters

Cosmos Health has entered a five-year agreement with Libytec Pharmaceutical to commercialize its type-2 diabetes medication DIABIT-IS X in Greece. Under the deal, Cosmos Health will supply the sitagliptin-based generic, while Libytec handles distribution and promotion to physicians, pharmacies, and hospitals. DIABIT-IS X is a generic alternative to Merck's Januvia, which together with Janumet generated approximately $4.5 billion in combined global sales in 2022. As a prescription medicine, it is expected to be accessible through Greece's national health insurance system, broadening its potential reach. The partnership is expected to contribute to Cosmos Health's revenue and cash-flow visibility.

Impact on stocks 3

Health Care▲ · 1 stocks
Cosmos Health Inc.
COSM
▲ PositiveDemandrelevance

Partnership to commercialize DIABIT-IS X in Greece expected to boost revenue and cash-flow visibility.

Biotech & Genomic Medicine▼ · 1 stocks
Merck & Company Inc
MRK
▼ NegativeCompetitionrelevance

DIABIT-IS X is a generic alternative to Merck's Januvia, potentially eroding market share.

Critical Materials & Supply Chain▲ · 1 stocks

Off-coverage companies 1

Libytec PharmaceuticalPrivate▲ Positive
Demandrelevance

Libytec will distribute and promote DIABIT-IS X, expanding its product portfolio.

© 2026 MarketDXNews